Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus
Abstract To analyze dalbavancin’s potential for long-term suppressive therapy in patients with infected ventricular assist devices (VAD), the VAD register of Heidelberg University Hospital was searched for patients who received dalbavancin for long-term suppression therapy. Clinical data, laboratory...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-99112-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850284415147573248 |
|---|---|
| author | Benedict Morath Sabrina Klein Ute Chiriac Yvonne Müller Lisa Koeppel Otto Frey Heike Lanzinger Philipp Schlegel Sonja Hamed Dennis Nurjadi Philipp Ehlermann Matthias Karck Anna L. Meyer |
| author_facet | Benedict Morath Sabrina Klein Ute Chiriac Yvonne Müller Lisa Koeppel Otto Frey Heike Lanzinger Philipp Schlegel Sonja Hamed Dennis Nurjadi Philipp Ehlermann Matthias Karck Anna L. Meyer |
| author_sort | Benedict Morath |
| collection | DOAJ |
| description | Abstract To analyze dalbavancin’s potential for long-term suppressive therapy in patients with infected ventricular assist devices (VAD), the VAD register of Heidelberg University Hospital was searched for patients who received dalbavancin for long-term suppression therapy. Clinical data, laboratory, and microbiological results were extracted. Healthcare utilization was analyzed by number of hospitalizations before and during dalbavancin therapy with a generalized linear mixed model. Drug safety was investigated with regard to liver and renal function, and thrombocyte count. Thirteen patients were included in the study; receiving a regimen of 1500 mg dalbavancin at day 1 and day 8 with repetition of the cycle at day 42. The mean follow-up time was 254 days (IQR 252). Eight patients were treated for driveline infection and five patients for driveline and blood stream infection, all of them caused by Staphylococcus aureus. The majority of patients (n = 11/13) underwent surgical wound debridement and intravenous antibiotic therapy before start of dalbavancin. Under dalbavancin therapy, no blood stream infection was observed and significantly fewer hospitalizations occurred with an odds ratio of 0.27 (p < 0.001). In four patients, elevations of liver transaminases were detected and led to discontinuation of dalbavancin therapy in one patient. |
| format | Article |
| id | doaj-art-ece3bf36a8a540b982834fb3bfaeab66 |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-ece3bf36a8a540b982834fb3bfaeab662025-08-20T01:47:34ZengNature PortfolioScientific Reports2045-23222025-05-011511910.1038/s41598-025-99112-7Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureusBenedict Morath0Sabrina Klein1Ute Chiriac2Yvonne Müller3Lisa Koeppel4Otto Frey5Heike Lanzinger6Philipp Schlegel7Sonja Hamed8Dennis Nurjadi9Philipp Ehlermann10Matthias Karck11Anna L. Meyer12Hospital Pharmacy, Heidelberg University HospitalDepartment of Infectious Diseases, Medical Microbiology and Hygiene, Medical Faculty Heidelberg, Heidelberg UniversityHospital Pharmacy, Heidelberg University HospitalDepartment of Cardiac Surgery, Heidelberg University HospitalDepartment of Infectious Disease and Tropical Medicine, Heidelberg UniversityHospital Pharmacy, General Hospital HeidenheimHospital Pharmacy, General Hospital HeidenheimDepartment of Cardiology, Heidelberg University HospitalDepartment of Cardiology, Heidelberg University HospitalDepartment of Infectious Diseases, Medical Microbiology and Hygiene, Medical Faculty Heidelberg, Heidelberg UniversityDepartment of Cardiology, Heidelberg University HospitalDepartment of Cardiac Surgery, Heidelberg University HospitalDepartment of Cardiac Surgery, Heidelberg University HospitalAbstract To analyze dalbavancin’s potential for long-term suppressive therapy in patients with infected ventricular assist devices (VAD), the VAD register of Heidelberg University Hospital was searched for patients who received dalbavancin for long-term suppression therapy. Clinical data, laboratory, and microbiological results were extracted. Healthcare utilization was analyzed by number of hospitalizations before and during dalbavancin therapy with a generalized linear mixed model. Drug safety was investigated with regard to liver and renal function, and thrombocyte count. Thirteen patients were included in the study; receiving a regimen of 1500 mg dalbavancin at day 1 and day 8 with repetition of the cycle at day 42. The mean follow-up time was 254 days (IQR 252). Eight patients were treated for driveline infection and five patients for driveline and blood stream infection, all of them caused by Staphylococcus aureus. The majority of patients (n = 11/13) underwent surgical wound debridement and intravenous antibiotic therapy before start of dalbavancin. Under dalbavancin therapy, no blood stream infection was observed and significantly fewer hospitalizations occurred with an odds ratio of 0.27 (p < 0.001). In four patients, elevations of liver transaminases were detected and led to discontinuation of dalbavancin therapy in one patient.https://doi.org/10.1038/s41598-025-99112-7DalbavancinVentricular assist deviceStaphylococcus aureusPersistent infection |
| spellingShingle | Benedict Morath Sabrina Klein Ute Chiriac Yvonne Müller Lisa Koeppel Otto Frey Heike Lanzinger Philipp Schlegel Sonja Hamed Dennis Nurjadi Philipp Ehlermann Matthias Karck Anna L. Meyer Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus Scientific Reports Dalbavancin Ventricular assist device Staphylococcus aureus Persistent infection |
| title | Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus |
| title_full | Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus |
| title_fullStr | Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus |
| title_full_unstemmed | Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus |
| title_short | Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus |
| title_sort | exploratory analysis of long term suppressive therapy with dalbavancin in ventricular assist device infections caused by staphylococcus aureus |
| topic | Dalbavancin Ventricular assist device Staphylococcus aureus Persistent infection |
| url | https://doi.org/10.1038/s41598-025-99112-7 |
| work_keys_str_mv | AT benedictmorath exploratoryanalysisoflongtermsuppressivetherapywithdalbavancininventricularassistdeviceinfectionscausedbystaphylococcusaureus AT sabrinaklein exploratoryanalysisoflongtermsuppressivetherapywithdalbavancininventricularassistdeviceinfectionscausedbystaphylococcusaureus AT utechiriac exploratoryanalysisoflongtermsuppressivetherapywithdalbavancininventricularassistdeviceinfectionscausedbystaphylococcusaureus AT yvonnemuller exploratoryanalysisoflongtermsuppressivetherapywithdalbavancininventricularassistdeviceinfectionscausedbystaphylococcusaureus AT lisakoeppel exploratoryanalysisoflongtermsuppressivetherapywithdalbavancininventricularassistdeviceinfectionscausedbystaphylococcusaureus AT ottofrey exploratoryanalysisoflongtermsuppressivetherapywithdalbavancininventricularassistdeviceinfectionscausedbystaphylococcusaureus AT heikelanzinger exploratoryanalysisoflongtermsuppressivetherapywithdalbavancininventricularassistdeviceinfectionscausedbystaphylococcusaureus AT philippschlegel exploratoryanalysisoflongtermsuppressivetherapywithdalbavancininventricularassistdeviceinfectionscausedbystaphylococcusaureus AT sonjahamed exploratoryanalysisoflongtermsuppressivetherapywithdalbavancininventricularassistdeviceinfectionscausedbystaphylococcusaureus AT dennisnurjadi exploratoryanalysisoflongtermsuppressivetherapywithdalbavancininventricularassistdeviceinfectionscausedbystaphylococcusaureus AT philippehlermann exploratoryanalysisoflongtermsuppressivetherapywithdalbavancininventricularassistdeviceinfectionscausedbystaphylococcusaureus AT matthiaskarck exploratoryanalysisoflongtermsuppressivetherapywithdalbavancininventricularassistdeviceinfectionscausedbystaphylococcusaureus AT annalmeyer exploratoryanalysisoflongtermsuppressivetherapywithdalbavancininventricularassistdeviceinfectionscausedbystaphylococcusaureus |